Critical Contribution of Ox40 Ligand to T Helper Cell Type 2 Differentiation in Experimental Leishmaniasis (original) (raw)
Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
Hideo Yagita
2004
View PDFchevron_right
Modulation of T-Cell Costimulation as Immunotherapy or Immunochemotherapy in Experimental Visceral Leishmaniasis
Richard Fichtl
Infection and Immunity, 2003
View PDFchevron_right
Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic pathways in cancer immunosurveillance: molecular mechanisms and prospects for therapy
Thomas Griffith
Research and Reports in Biochemistry, 2014
View PDFchevron_right
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon -Dependent Natural Killer Cell Protection from Tumor Metastasis
Hideo Yagita
Journal of Experimental Medicine, 2001
View PDFchevron_right
Immunomodulation by chemotherapeutic agents against Leishmaniasis
Debanjan Mukhopadhyay
International Immunopharmacology, 2011
View PDFchevron_right
T Cell Reactions Elude Tumor-Specific and Allogeneic Cells Engineered to Express TRAIL A "Stealth Effect": Adenocarcinoma
Paola Bernabei
2000
View PDFchevron_right
Targets for immunochemotherapy in leishmaniasis
Debanjan Mukhopadhyay
Expert review of anti-infective therapy, 2012
View PDFchevron_right
immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis
Rajiv Srivastava
View PDFchevron_right
Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects
Om Singh
Frontiers in immunology, 2014
View PDFchevron_right
Antagonizing Deactivating Cytokines To Enhance Host Defense and Chemotherapy in Experimental Visceral Leishmaniasis
Joseph Sypek
Infection and Immunity, 2005
View PDFchevron_right
TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells
Daniela Wesch
Frontiers in Immunology, 2019
View PDFchevron_right
Live Attenuated Leishmania donovani p27 Gene Knockout Parasites Are Nonpathogenic and Elicit Long-Term Protective Immunity in BALB/c Mice
Dr. Angamuthu Selvapandiyan
The Journal of Immunology, 2013
View PDFchevron_right
Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis
Gordon Ruthel
PLoS pathogens, 2013
View PDFchevron_right
A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions
Gianni Garotta
Journal of immunology (Baltimore, Md. : 1950), 1999
View PDFchevron_right
TRAIL and its receptors as targets for cancer therapy
Hideo Yagita
Cancer Science, 2004
View PDFchevron_right
Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load
Lynn Soong
Scientific Reports, 2019
View PDFchevron_right
Critical Role for Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development
Hideo Yagita
Journal of Experimental Medicine, 2002
View PDFchevron_right
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
Mark Tuthill
Oncogene, 2014
View PDFchevron_right
Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges
Heshu Rahman
Frontiers in Immunology, 2021
View PDFchevron_right
Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody
Anil Shanker
JNCI Journal of the National Cancer Institute, 2008
View PDFchevron_right
FasL and TRAIL signaling in the skin during cutaneous leishmaniasis - implications for tissue immunopathology and infectious control
Bence Rethi
Frontiers in immunology, 2012
View PDFchevron_right
CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer
Hideo Yagita
Journal of Clinical Investigation, 2008
View PDFchevron_right
Anti-Leishmania activity of mucosal-associated invariant T-cells
Eleanor Saunders
2021
View PDFchevron_right
Compartmentalized cytotoxic immune response leads to distinct pathogenic roles of natural killer and senescent CD8+ T cells in human cutaneous leishmaniasis
Herbert Guedes
Immunology, 2020
View PDFchevron_right
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
P. Kanakaraj, L. Pukac, Xiao-Tao Yao
British journal of cancer, 2005
View PDFchevron_right
CD95 (FAS) and CD178 (FASL) induce the apoptosis of CD4+ and CD8+ cells isolated from the peripheral blood and spleen of dogs naturally infected with Leishmania spp
Larissa Melo
Veterinary parasitology, 2013
View PDFchevron_right
Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells
Valerie Wiersma
Clinical Cancer Research, 2011
View PDFchevron_right
Leishmania donovani skews the CD56+ Natural Killer T cell response during human visceral leishmaniasis
Fauzia Jamal
Cytokine, 2015
View PDFchevron_right
Metastasis Suppressor Function of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-R in Mice: Implications for TRAIL-Based Therapy in Humans?
Anne Grosse-Wilde
Cancer Research, 2008
View PDFchevron_right